Skip to main content

Table 3 Clinical management of early- and late-irAEs

From: Immunotherapy Bridge 2019 and Melanoma Bridge 2019: meeting abstracts

 

Early-irAEs (patients-%)

Late-irAEs (patients-%)

P value

Any grade irAEs

175

110

 

Single-site irAEs

112 (64.0)

93 (84.5)

0.1339

Multiple-site irAEs

63 (36.0)

17 (15.4)

0.0040

Management

 No intervention (only supportive)

87 (49.7)

55 (50.0)

0.9783

 Corticosteroids without discontinuation

69 (39.4)

38 (34.5)

0.5754

 Corticosteroids with temporary discontinuation

19 (10.9)

6 (5.5)

0.1488

 Corticosteroids with permanent discontinuation

–

11 (10)

0.0001